Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sequenced aromatase inhibitor use associated with lower risk of endometrial cancer in tamoxifen-treated breast cancer patients: a population-based study

Date

08 Oct 2016

Session

Poster Display

Presenters

Sung-Chao Chu

Citation

Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374

Authors

S. Chu1, C. Hsieh2, T. Wang1, M. Hong3, T. Chu3

Author affiliations

  • 1 Hematology/oncology, Hualian Buddhist Tzu Chi General Hospital, 970 - Hualian/TW
  • 2 Public Health, Tzu-Chi University, Hualian/TW
  • 3 Obstetrics And Gynecology, Hualian Buddhist Tzu Chi General Hospital, Hualian/TW
More

Resources

Background

Western studies reveal older ( >50 years) breast cancer survivors with tamoxifen treatment had higher risk of endometrial cancer. The purpose of the study is to disclose whether sequenced aromatase inhibitor (AI) use could reduce the incidence of endometrial cancer in tamoxifen-treated breast cancer patients.

Methods

A population-based cohort of 40740 newly diagnosed breast cancer patients with and without antiestrogen therapy were identified from the Taiwan National Health Insurance Database from 1999 to 2012. Endometrial cancer risk was compared with Cox regression analysis with competing risk analysis by the Fine and Gray method, and adjusted for antiestrogen use, age, diabetes, hypertension and chemotherapy.

Results

During the 14-year study period, 135 patients were diagnosed with subsequent endometrial cancers and the incidence per 105 person-years patients were 24.8, 91.9 and 46.7 in nonuser (n = 14588), tamoxifen (n = 19302) and AI-included group (n = 6850), respectively. When compared with nonuser, tamoxifen had a higher risk of endometrial cancer (14-year incidence 1.4% vs 0.3%; HR 3.92; 95% CI, 2.38 to 6.46; p 50 years) tamoxifen-treated patients had higher risk of endometrial cancer. But our younger (40-50 years) tamoxifen-treated patients also had higher risk of endometrial cancer (HR 3.74; 95% CI, 1.65 to 8.48; p = 0.0015). The 4004 tamoxifen-treated patients taking sequenced AI were matched with 8008 tamoxifen-only patients after adjusting for age, cumulative dose of tamoxifen and year of breast cancer diagnosis. The risk of endometrial cancer was lower in patients with sequenced AI (14-year incidence 0.6% vs 1.4%; HR 0.4; 95% CI, 0.22 to 0.73; p = 0.0028).

Conclusions

In Taiwan, not only older( >50 years) but younger (40-50 years) patients with tamoxifen treatment had higher risk of subsequent endometrial cancer. The risk of endometrial cancer still increased after patients had discontinued tamoxifen for several years. Sequenced AI use may reverse endometrial cancer risk in tamoxifen-treated breast cancer patients.

Clinical trial identification

Not applicable

Legal entity responsible for the study

This study was approved by the Research Ethics Committee of Buddhist Tzu Chi General Hospital, Hualien, Taiwan (IRB101-98).

Funding

The National Science Council of the Republic of China, and Buddhist Tzu Chi General Hospital Taiwan were appreciated for supporting this research under Contract No. NSC 101-2314-B-303-020 and TCRD102-52.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings